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Background and Aims: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. There is
a need to clearly define fibrosis progression in NAFLD in order to inform clinical trial development. The aim of this study
was to assess rates of fibrosis progression in a large cohort of NAFLD patients with paired liver biopsies.
Methods: NAFLD patients without baseline cirrhosis with 2 sequential liver biopsies were identified from 7 European
specialist centres. Clinical and laboratory data were collected from the time of liver biopsy. Histological scoring was
performed according to the Kleiner criteria.
Results: 321 patients with NAFLD (mean age 48±12 years; 63% male; mean BMI 32.6±6.4 Kg/m2; 32% diabetic; 69%
NASH) who had sequential biopsies conducted >1 year apart were identified. Overall, 111 patients (35%) had fibrosis
progression between biopsies over median follow up period of 4.1 yrs (range 1-22.6 yrs). The average progression rate
was 0.038 ± 0.42 stages/year (range 0-1.73 stages/year) in the whole cohort and 0.37±0.31 stages/year in the
progressors. 26 patients (8% of whole cohort, 23% of progressors) were “rapid progressors” (progression >0.5
stages/year). The Table shows the distribution of fibrosis progression at index and follow up biopsy and rate of
progression according to baseline fibrosis stage. There was no significant difference in the proportion of patients with
NASH or NAFL at baseline who had fibrosis progression (36% vs 30% p=0.33 respectively), and the overall fibrosis rate
was similar in patients with NASH or NAFL at the index biopsy (0.02 ± 0.048 vs 0.06 ± 0.23 stages/year p = 0.20
respectively). There was a positive association between the presence of moderate/severe steatosis and fibrosis
progression (p<0.001), but no relationship with the NAFLD activity score and fibrosis progression.
 
Baseline
Fibrosis
Follow up fibrosis stage    
Stage 0 Stage 1 Stage 2 Stage 3 Stage 4 Total Progression
(mean rate/yr)
Regression
(mean rate/yr)
Stage 0 74 25 5 5 0 109 32% (0.42 ± 0.39) 0% (0)
Stage 1 24 41 16 18 4 103 37% (0.37 ± 0.30) 23% (-0.41 ± 0.34)
Stage 2 7 12 24 18 5 66 35% (0.35 ± 0.28) 29% (-0.61 ± 0.64)
Stage 3 2 3 7 16 15 43 35% (0.35 ± 0.28) 28% (-0.60 ± 0.77)
Total 107 81 52 57 24 321 35% (0.37 ± 0.31) 17% (-0.52 ± 0.56)
Conclusions: Fibrosis progression rates are variable in NAFLD. The severity of steatosis is an important histological
factor in predicting fibrosis progression. Fibrosis progression occurs in a similar proportion of individuals irrespective of
baseline fibrosis stage.
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